More than two years after Pfizer tied the knot with machine learning firm CytoReason in an AI-focused deal, the two companies have agreed to keep the partnership alive for at least five more years.

NEW YORK – Elicio Therapeutics said Tuesday that it received a $2.8 million grant from the Gastro-Intestinal Research Foundation in Chicago that it will use to develop two cancer vaccines.

Experts from Umoja Biopharma dive into cell therapy development in this episode of the Drug Solutions Podcast, including the greatest advancements in cell therapy to date, areas for improvement, the biggest trends in cell therapy development, and retention as a pain point.

The Founder of the Sepsis Alliance, Carl Flatley, is on a mission to raise awareness for sepsis, and he is doing so by riding his bike across the state of Florida to honor his daughter, Erin, who passed away because of sepsis.

We’re developing a pipeline of innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases. Our lead program, REN-001, is being developed for BAG3-associated dilated cardiomyopathy (DCM) and uses gene transfer technology to address the monogenic cause of this severe form of heart failure.

In July, SOTIO Biotech launched an aggressive phase 2 basket trial of its lead candidate, the IL-15-targeting SOT101, as monotherapy and in combination with pembrolizumab (Keytruda) in patients with selected relapsed/refractory advanced/metastatic solid tumors.

Etkin explains that in the cerebral cortex—the outermost layer of the brain—are systems responsible for a number of higher functions, including cognitive functions like planning,

Ashvattha Therapeutics today announced that the first patient has been enrolled in a two-stage Phase 2 clinical study of D-4517.2, an HDT with potent anti-VEGF activity.